PubMed RSS Feed - - Migraine, triptans, and the risk of developing rosacea: A population-based study within the United Kingdom.

[rss]

Migraine, triptans, and the risk of developing rosacea: A population-based study within the United Kingdom.

J Am Acad Dermatol. 2013 May 1;

Authors: Spoendlin J, Voegel JJ, Jick SS, Meier CR

Abstract
BACKGROUND: Rosacea is a common skin disease, involving neurogenic inflammation and neurovascular dysregulation. Migraine has been associated with vascular changes and sterile inflammation. The 2 diseases have been associated over decades, but evidence is scarce. Triptans have vasoconstricting and antiinflammatory properties, but a potential impact of this drug class on rosacea remains uninvestigated. OBJECTIVE: We sought to analyze the association between migraine or triptan exposure and the risk of developing rosacea within the United Kingdom. METHODS: We conducted a case-control study using the United Kingdom-based General Practice Research Database. We identified patients with incident rosacea between 1995 and 2009 (cases), and matched 1 rosacea-free control subject to each case. We compared the prevalence of diagnosed migraine and exposure to triptans before the first-time rosacea diagnosis between cases and controls using multivariate conditional logistic regression. RESULTS: Among 53,927 cases and 53,927 controls, we observed a small overall association between rosacea and migraine in women (adjusted odds ratio 1.22, 95% confidence interval 1.16-1.29), but not in men. This effect was somewhat more distinct in female migraineurs aged 50 to 59 years (odds ratio 1.36, 95% confidence interval 1.21-1.53). Female triptan users also revealed slightly increasing risk estimates with increasing age, with the highest odds ratio of 1.66 (95% confidence interval 1.30-2.10) in women aged 60 years or older. LIMITATIONS: This is a retrospective case-control study, for which a certain degree of bias and confounding cannot be ruled out. CONCLUSIONS: We observed a slightly increased risk for female migraineurs to develop rosacea, particularly in women with severe migraine aged 50 years or older.

PMID: 23643255 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23643255?dopt=Abstract = URL to article